Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drugging KRAS: current perspectives and state-of-art review
Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Adagrasib: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 3, pp. 275-285
Closed Access | Times Cited: 82
New insight into circRNAs: characterization, strategies, and biomedical applications
Xin-Yi Feng, Shun-Xin Zhu, Ke‐Jia Pu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 46
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Lei Wang, Wang‐Qing Liu, Sylvain Broussy, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 36
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 19
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives
Mitsunobu Takeda, Shoma Yoshida, Takuya Inoue, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 428-428
Open Access | Times Cited: 2
Annual review of KRAS inhibitors in 2022
Hao Wang, Lingling Chi, Fuqiang Yu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115124-115124
Closed Access | Times Cited: 32
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Ramesh Kumar, Wanjin Hong
Cells (2024) Vol. 13, Iss. 7, pp. 564-564
Open Access | Times Cited: 12
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
Qing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 12, pp. 1630-1639
Closed Access | Times Cited: 10
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 8
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 1
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Cen Liu, Danyang Ye, Hongliu Yang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 18
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
New prospectives on treatment opportunities in RASopathies
Bruce D. Gelb, Marielle E. Yohe, Cordula M. Wolf, et al.
American Journal of Medical Genetics Part C Seminars in Medical Genetics (2022) Vol. 190, Iss. 4, pp. 541-560
Open Access | Times Cited: 23
Small molecular inhibitors for KRAS-mutant cancers
Xuan Wu, Wenping Song, Cheng Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Fernand Bteich, Mahshid Mohammadi, T. Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12030-12030
Open Access | Times Cited: 14
Updated Management of Colorectal Cancer Liver Metastases: Scientific Advances Driving Modern Therapeutic Innovations
Ranish K. Patel, Shahrose Rahman, Issac R. Schwantes, et al.
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 16, Iss. 6, pp. 881-894
Open Access | Times Cited: 14
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
Dan Zhao, Yu Liu, Fengchao Yi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115698-115698
Closed Access | Times Cited: 13
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor
Yan Lv, Zixuan Yang, Yiming Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2487-2511
Closed Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top